Vericel (FRA:ATQP) Institutional Ownership: 72.90% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ATQP Vericel Corp FRA:ATQP
83 GF Score
Price €39.20
GF Value €48.15
! 7 Warning Signs
View Full Analysis

What is Vericel Institutional Ownership?

Vericel FRA:ATQP +1.55% 83 Institutional Ownership is 72.90% as of Jul. 27, 2026. GuruFocus rates FRA:ATQP with a GF Score™ of 83/100 and a GF Value™ of €48.15. The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vericel's institutional ownership is 72.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vericel's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vericel's Float Percentage Of Total Shares Outstanding is 77.58%.

Vericel Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Vericel's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vericel Institutional Ownership Chart

Vericel Historical Data

The historical data trend for Vericel can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 81.70 83.09 84.81 80.53 79.55 79.29 73.21 71.16 70.99 72.90
FRA:ATQP
83GF Score
Vericel Corp FRA:ATQP
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vericel Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 72.90% mean?
Vericel (FRA:ATQP) has a Institutional Ownership of 72.90% as of Jul. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Vericel and its competitors.
Is Vericel's Institutional Ownership too high?
Vericel's current Institutional Ownership is 72.90%. Overall, Vericel has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Vericel's Institutional Ownership compare to KLRA and MLYS?
Vericel's Institutional Ownership of 72.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Vericel and its competitors. Vericel's current Institutional Ownership is 72.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Vericel (FRA:ATQP) has a current Institutional Ownership of 72.90%. The stock's GF Value™ is €48.15, compared to a current price of €39.20 — trading 18.6% below its estimated fair value. The current Institutional Ownership is 72.90%. Vericel's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Vericel (FRA:ATQP), the current Institutional Ownership is 72.90% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vericel (FRA:ATQP) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of €39.20 is trading 18.6% below its estimated GF Value™ of €48.15.

Key valuation signals for FRA:ATQP:

  • Institutional Ownership: 72.90%
  • GF Value™: €48.15 vs. price of €39.20 (18.6% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges VCEL:USA
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
83GF Score

Get the complete analysis for FRA:ATQP

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.20
Price
€48.15
GF Value